Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Thursday, February 11, 2016

Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS


Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS, ECTRIMS 2015 Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long Phase 3 study were also published in the New England Journal of Medicine (NEJM), in a manuscript entitled Daclizumab HYP Versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
ZINBRYTA TM (daclizumab high-yield process) is a compound being developed by Biogen and AbbVie for the treatment of relapsing-remitting multiple sclerosis (RRMS). It consists of a humanized monoclonal antibody that binds to the receptor subunit CD25 of interleukin-2 (IL-2), highly expressed in immune T-cells. This type of immune cells is overly expressed in MS, so ZINBRYTA theoretically depletes the overly-activated cells and increases cells that regulate the immune response (NK cells). The study DECIDE was designed with the objective of comparing clinical results of subcutaneously-delivered ZINBRYTA (every four weeks) and the commonly used intramuscular injection (IM) of interferon beta-1a.
The results covered a range of clinical measures on MS disease activity, and showed that a greater percentage of patients treated with ZINBRYTA TM exhibited no evidence of clinical disease activity and disease-related lesions (24.6%) in comparison to IM-interferon beta-1a treated patients (14.2%). Furthermore, ZINBRYTA was shown to improve cognitive processing speed, reduce cognitive decline and decrease risk of 24-week disease progression.

                                            ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News 
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information 
by opting-in to our website: click here - thank you
.===================================

No comments: